Jaguar Health, Inc. (JAGX)

NCM – Цена в реальном времени. Валюта: USD

0.77

-0.02 (-2.81%)

Рынок открыт: Aug 12, 2026, 12:01 PM EDT

0.78

-0.01 (-1.05%)

Предыдущая сессия: Aug 11, 2026, 7:59 PM EDT

05.08.2026

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

As announced , Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure (IF) indications Presentation at ESPGHAN 2026 described additional groundbreaking results of evaluation of crofelemer as adjunctive oral therapy for the treatment of pediatric IF, which demonstrate reduction of parenteral support normalized to body weight of up to 48% in patient with the ultrarare microvillus inclusion disease (MVID) SAN FRANCISCO, CA / ACCESS Newswire / August 5, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that its wholly-owned subsidiary Napo Pharmaceuticals, Inc. (collectively, with Jaguar Health, Inc., "Jaguar") has satisfied the conditions required to receive payment of the non-dilutive $2 million holdback amount from Future Pak, LLC ("Future Pak") related to the U.S. commercial licensing agreement Jaguar entered in January 2026 with a Future Pak affiliate. As announced, Jaguar was provided with a partial upfront fee of $16 million of non-dilutive capital upon closing of the agreement.

Видео

No Data

There is no data to display

Пресс-релизы

05.08.2026

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Jaguar Health, Inc. (JAGX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Jaguar Health, Inc. (JAGX)

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Видео

No Data

Пресс-релизы

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Видео

No Data

Пресс-релизы

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Search stocks

Jaguar Health, Inc. (JAGX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Jaguar Health, Inc. (JAGX)

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Видео

No Data

Пресс-релизы

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1

Видео

No Data

Пресс-релизы

Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1